NERM
FLGT icon

New England Research & Management’s Fulgent Genetics FLGT Stock Holding History

New England Research & Management’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-13,800
Closed -$719K – 176
2020
Q4 		$719K Buy
+13,800
New +$577K 0.44% 78

Other funds holding FLGT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NI
Nepsis Inc Minneapolis, Minnesota $295M AUM 35.44% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

New England Research & Management's FLGT Position: Q1 2021 in Review

New England Research & Management sold out of Fulgent Genetics (FLGT) in Q1 2021, closing a stake of 13,800 shares — an estimated $719K sold.

New England Research & Management first reported a position in FLGT in Q4 2020 and held it in 1 quarter. The position peaked at $719K in Q4 2020. 256 funds tracked by Wall St. Rank hold FLGT as of Q1 2021.

  • New England Research & Management reported no remaining Fulgent Genetics position as of Q1 2021 after selling out during the quarter.
  • New England Research & Management sold 13,800 Fulgent Genetics shares in Q1 2021, an estimated $719K.
  • New England Research & Management first reported a position in Fulgent Genetics in Q4 2020 and held it in 1 quarter.
  • New England Research & Management's Fulgent Genetics position peaked at $719K in Q4 2020.
  • 256 funds tracked by Wall St. Rank held Fulgent Genetics as of Q1 2021.

Based on New England Research & Management's 13F filing for Q1 2021, filed 16 Apr 2021.